Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma.
Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma.
复制标题
DOI：
10.1155/2015/208076
复制
发表时间：
2015
影响因子：
--
通讯作者：
Pirtoli L
中科院分区：
文献类型：
--
作者：
Tini P;Belmonte G;Toscano M;Miracco C;Palumbo S;Pastina P;Battaglia G;Nardone V;Butorano MA;Masucci A;Cerase A;Pirtoli L
胶质母细胞瘤中 EGFR 失调可能会使关键自噬蛋白 Beclin1 失活。 EGFR 蛋白高表达和 Beclin1 蛋白表达低分别与肿瘤进展和不良预后相关。 EGFR 和 Beclin1 的高 (H) 表达与低 (L) 表达相比，与 117 名化疗和放疗后患者的主要临床数据相关。 H-EGFR 与低卡诺夫斯基表现和较差的神经功能状态、较高的同步多灶性发生率、较差的放射学反应证据、较短的无病进展 (PDFS) 和总生存期 (OS) 相关。 H-Beclin1 病例表现出更好的卡诺夫斯基表现状态、更高的客观缓解发生率、更长的 PDFS 和 OS。分层 L-EGFR 和 H-Beclin1 表达与治疗后放射学反应发生率、单灶疾病和更好预后的相关性出现相互强化效应，从而确定更长的 OS 组（中位 OS 为 30 个月，而 L-EGFR 为 18 个月，H-Beclin1 为 15 个月，所有 GB 为 11 个月）(P = 0.0001)。 L-EGFR + H-Beclin1 组合表达可能代表识别相对有利的临床表现和预后的生物标志物，从而设想可能的 EGFR/Beclin1 靶向治疗。
Dysregulated EGFR in glioblastoma may inactivate the key autophagy protein Beclin1. Each of high EGFR and low Beclin1 protein expression, independently, has been associated with tumor progression and poor prognosis. High (H) compared to low (L) expression of EGFR and Beclin1 is here correlated with main clinical data in 117 patients after chemo- and radiotherapy. H-EGFR correlated with low Karnofsky performance and worse neurological performance status, higher incidence of synchronous multifocality, poor radiological evidence of response, shorter progression disease-free (PDFS), and overall survival (OS). H-Beclin1 cases showed better Karnofsky performance status, higher incidence of objective response, longer PDFS, and OS. A mutual strengthening effect emerges in correlative power of stratified L-EGFR and H-Beclin1 expression with incidence of radiological response after treatment, unifocal disease, and better prognosis, thus identifying an even longer OS group (30 months median OS compared to 18 months in L-EGFR, 15 months in H-Beclin1, and 11 months in all GBs) (P = 0.0001). Combined L-EGFR + H-Beclin1 expression may represent a biomarker in identifying relatively favorable clinical presentations and prognosis, thus envisaging possible EGFR/Beclin1-targeted therapies.
登录
查看更多内容
影响因子：
8
作者：
Li, B;Yuan, M;Shu, HKG
通讯作者：
Shu, HKG
影响因子：
5.6
作者：
Palumbo, Silvia;Tini, Paolo;Pirtoli, Luigi
通讯作者：
Pirtoli, Luigi
影响因子：
45.3
作者：
MACDONALD, DR;CASCINO, TL;CAIRNCROSS, JG
通讯作者：
CAIRNCROSS, JG
影响因子：
158.5
作者：
Hegi, ME;Diserens, A;Stupp, R
通讯作者：
Stupp, R
影响因子：
4.8
作者：
Hatanpaa, Kimmo J.;Burma, Sandeep;Habib, Amyn A.
通讯作者：
Habib, Amyn A.